Top Markets
Coin of the day
Valeo Pharma Inc. Valeo Pharma Inc.

Valeo Pharma Inc.

VPHIF
Rank in Stocks #41805
Valeo Pharma Inc. is a Canadian specialty pharmaceutical firm dedicated to... Valeo Pharma Inc. is a Canadian specialty pharmaceutical firm dedicated to sourcing, licensing, and selling a variety of medicinal products, with a primary emphasis on respiratory, specialized, and hospital-grade generic drugs. Its extensive product lineup features prominent asthma medications like Enerzair Breezhaler (a triple-combination LABA/LAMA/ICS) and Atectura Breezhaler (a dual-combination LABA/ICS). The company also offers Redesca, crucial for preventing and treating deep vein thrombosis and pulmonary embolism. For neurological conditions, Valeo markets Onstryv, an add-on treatment for Idiopathic Parkinson's Disease in patients on stable Levodopa, and Benztropine, an anticholinergic for PD. Pain management is addressed with M-Eslon, an extended-release morphine sulfate, while Yondelis targets soft tissue sarcoma. Beyond these, the portfolio includes Hesperco, an immune-supporting bioflavonoid antioxidant; Ametop, a skin anesthetic used before venous procedures; Ethacrynate Sodium, a loop diuretic for high blood pressure and swelling; and Amikacin, an injectable antibiotic. Founded in 2003, Valeo Pharma Inc. is headquartered in Kirkland, Canada.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$9.87K
Change (1 day)
0.00%
Change (1 year)
-99.79%
Country
CA
Trade Valeo Pharma Inc. (VPHIF)

Category

P/B ratio for Valeo Pharma Inc. (VPHIF)
P/B ratio as of 2026 TTM: 0
According to Valeo Pharma Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Valeo Pharma Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors